Gonorrhea Therapeutics Market to grow by USD 506.68 million from 2022 to 2027; North America accounts for 39% of market growth - Technavio

NEW YORK, Nov. 21, 2023 /PRNewswire/ -- The gonorrhea therapeutics market size is expected to grow by USD 506.68 million from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 5.47% during the forecast period, according to Technavio Research. The market has been segmented by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), therapy (monotherapy and combination therapy), and geography (North America, Europe, Asia, and the Rest of World (ROW)). North America accounts for 39% of market growth during the forecast period. The US is the main country in North America that is significantly contributing to the growth of the gonorrhea therapeutics market due to the presence of prominent market players such as Merck and Pfizer. Hence, the presence of such market players drives the market growth in North America. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read Free PDF Sample Report

Company Profile:

Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Ltd., Debiopharm International SA, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Mayne Pharma Group Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Therapyx Inc., and Entasis Therapeutics

Apotex Inc: The company offers gonorrhea therapeutics such as Apotex Ceftriaxone Injection.

• To gain access to more company profiles available with Technavio, buy the report!

Gonorrhea Therapeutics Market: Segmentation Analysis

• The market share growth of the hospital pharmacies segment is significant during the forecast period. There is a growing adoption of integrated healthcare models across hospitals that focus on coordinated and patient-centered care. In addition, this segment plays a crucial role by ensuring that medications are managed effectively throughout a patient's stay, from admission to discharge. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth.

 Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report

"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio

Gonorrhea Therapeutics Market: Driver & Trend:

• The rising prevalence of gonorrhea drives the market growth during the forecast period. Factors such as growing awareness, increased healthcare access, availability of diagnostic tests, resistance patterns, reporting practices, and financial constraints limit the abilities of public healthcare officials to check disease patterns precisely fuelling the rising prevalence of gonorrhea. Hence, such factors drive the market growth.
• High-risk complications associated with gonorrhea
• Growing use of new diagnostic tests

Trend -

The advent of vaccines for the prevention of gonorrhea is a primary trend in the market. There is an increasing concern across the world regarding the prevalence of gonorrhea as it is significantly affecting the reproductive health of people and increasing the spread of the human immunodeficiency virus (HIV). due to the rapid emergence of antibiotic-resistant strains of this bacterium. However, the emergence of vaccines is positively impacting the market which in turn drives the market.
Strategic alliances among market players are a key trend in the tyrosine kinase inhibitors market. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.

Related Reports:

The insomnia therapeutics market size is estimated to grow by USD 1,002.93 million at a CAGR of 5.49% between 2022 and 2027. 

The global pneumococcal vaccine market size is estimated to grow by USD 2,820.53 million at a CAGR of 5.81% between 2022 and 2027. 

What are the key data covered in this gonorrhea therapeutics market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the gonorrhea therapeutics market between 2022 and 2027.
• Precise estimation of the gonorrhea therapeutics market size and its contribution to the market in focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the gonorrhea therapeutics market across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of gonorrhea therapeutics companies.

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Distribution Channel

Market Segmentation by Therapy

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio